IVD China this week: Wondfo, BGI, Fapon, ZZBio

First in Africa! Wondfo and University of Nairobi Joint Training Center Officially Opened

Recently, the joint training center built by Wondfo Biotech and University of Nairobi was officially opened. As the first laboratory medicine training center built by a Chinese IVD company in Africa, the center is located in Kenyatta National Hospital and will provide professional training for more than 500 laboratory staff and students every year. The center construction is a strong testimony of Wondfo's active global industry-academia-research cooperation and participation in the construction of global health, which will effectively help to improve the local diagnosis and treatment services.

BGI achieved a revenue of CNY2.071 billion in the first half of 2023

BGI disclosed its 2023 half-yearly report. 

The company realized operating income of CNY2.071 billion in the first half of the year, realized net profit of CNY51.7441 million, and realized net profit of CNY56.0348 million of non-deductible net profit.

Among them, the company's tumor prevention and control business achieved revenue of CNY218 million, up 38% year-on-year. The reproductive health business achieved revenue of CNY566 million, basically flat year-on-year. The multi-omics business achieved revenue of CNY328 million, up 4.58% year-on-year.

​

Fapon was awarded the title of "The 'chain master' enterprise of the first batch of key industry chain (biomedicine and high-end medical devices) in Dongguan"

Dongguan Science and Technology Bureau organized the selection of the first batch of key industry chain (biomedicine and high-end medical devices) "chain master" enterprises. Guangdong Fapon Biologicals Co., Ltd., the subsidiary of Fapon Biologicals Co., Ltd., won the title with its strategic advantage in open platform ecosystem of in vitro diagnostic reagents core raw materials and reagent solutions.

Zhenzhun Bio-Tech's Digital PCR System Received the CE marking

Zhenzhun Bio-Tech focuses on the development of digital PCR instrument platforms and related applications, and it has always been Zhenzhun Bio's mission and vision to popularize digital PCR technology and products. 

Recently, the company's full range of digital PCR instrumentation products have passed the evaluation of various indicators and successfully obtained the European Union CE certification, which marks the beginning of Zhenzhun Bio-Tech's entry into the international market and a new stage of globalization and popularization!

​

​